NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

RecruitingPhase 2

Sponsor: West China Hospital

Conditions: Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

Interventions: JWK001, Aflibercept (2.0 mg)

Countries: China

This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular age-related macular degeneration.

Eligibility overview

Sex: ALL

Age: 50 Years to 85 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Written informed consent and ability to comply with the study protocol.
2. Male or female, aged 50-85 years.
3. Active subfoveal MNV secondary to nAMD requiring anti-VEGF treatment.
4. Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center;
5. Study-eye BCVA of 19-78 ETDRS letters.
6. Pseudophakic study eye.

Exclusion Criteria:

1. Any ocular condition other than nAMD that may affect vision, study assessments, treatment safety, or interpretation of results.
2. Intraocular surgery or intraocular corticosteroid treatment within 4 weeks at screening.
3. Any ocular condition making the study eye unsuitable for subretinal injection.
4. Active ocular infection or inflammation, or a history of idiopathic or autoimmune uveitis.
5. Monocular status or non-study-eye BCVA \<19 ETDRS letters.
6. Clinically significant systemic disease or infection, malignancy, prohibited concomitant treatment, prior gene therapy, or recent participation in another clinical trial.
7. Any other condition considered by the investigator to make the subject unsuitable for participation.

Locations (16)

Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Jilin City, Changchun, China
Chongqing, Chongqing Municipality, China
Shantou, Guangdong, China
Zhejiang, Hangzhou, China
Harbin, Heilongjiang, China
Zhengzhou, Henan, China
Wuhan, Hubei, China
Nanjing, Jiangsu, China
Shanghai, Shanghai Municipality, China
Taiyuan, Shanxi, China
Taiyuan, Shanxi, China
Chengdu, Sichuan, China
Tianjin, Tianjin Municipality, China
Kunming, Yunnan, China